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A cross-sectional study of 132 adults attending an HIV clinic in Cape Town, South Africa, was
conducted to determine predictors of low plasma vitamin A and Zn levels. No patients were on
antiretroviral therapy. The possible confounding effect of the acute-phase response was con-
trolled by including C-reactive protein levels in multivariate analysis and by excluding active
opportunistic infections. Retinol levels were low (,1·05mmol/l) in 39 % of patients with early
disease (WHO clinical stages I and II) compared with 48 and 79 % of patients with WHO
stage III and IV respectively (P,0·01). Plasma Zn levels were low (,10·7mmol/l) in 20 % of
patients with early disease v. 36 and 45 % with stage III and IV disease respectively
(P,0·05). C-reactive protein levels were normal in 63 % of subjects. Weak, positive associations
were found between CD4+ lymphocyte count and plasma levels of retinol (r 0·27; 95 % CI 0·1,
0·43) and Zn (r 0·31; 95 % CI 0·25, 0·46). Multivariate analysis showed the following indepen-
dent predictors of low retinol levels: WHO stage IV (odds ratio 3·4; 95 % CI 2·1, 5·7) and body
weight (odds ratio per 5 kg decrease 1·15; 95 % CI, 1·08, 1·25), while only body weight was
significantly associated with low Zn levels (OR per 5 kg decrease 1·19; 95 % CI 1·09, 1·30).
CD4+ lymphocyte count ,200/ml was not significantly associated with either low retinol or
Zn levels. In resource-poor settings, simple clinical features (advanced disease and/or weight
loss) are associated with lowered blood concentrations of vitamin A and/or Zn. The clinical
significance of low plasma retinol and/or Zn levels is unclear and more research is required to
establish the role of multiple micronutrient intervention strategies in HIV disease.
HIV infection: Vitamin A: Zinc: C-Reactive Protein: Africa
HIV infection continues to increase worldwide, and an
estimated 28·5 million adults and children are infected in
sub-Saharan Africa alone (Joint United Nations Programme
on HIV/AIDS (UNAIDS) 2002). Most studies investigating
the micronutrient status of HIV-infected populations have
reported low serum or plasma levels of micronutrients
such as vitamins A, E, B6, B12, C and carotenoids, as
well as trace elements such as Zn and Se. However, limited
results exist for developing countries (Semba & Tang,
1999).
Vitamin A plays a central role in the growth and
function of T and B cells, antibody responses and mainten-
ance of mucosal epithelia (Semba, 1994). Low blood levels
of vitamin A are associated with accelerated disease
progression and increased mortality in HIV-infected
adults (Semba et al. 1993, 1995; Baum et al. 1995, 1997;
Tang et al. 1997). In addition, low concentrations of
vitamin A may be associated with increased mother-to-
child transmission of HIV, higher infant mortality and
child growth failure (Semba et al. 1994, 1997a,b; Green-
berg et al. 1997).
In Africa, low blood vitamin A concentrations
(,1·05mmol/l) have been reported in 50–63 % of HIV-
infected pregnant women (Semba, 1997; Moodley et al.
1998). Approximately one-third of seropositive adults
attending an outpatient clinic in Uganda, had lowered
serum vitamin A levels (Semba, 1997). Another study,
conducted among in-patients co-infected with tuberculosis
in Rwanda, showed that 29 % of patients presented with
low blood vitamin A levels (Rwangabwoba et al. 1998).
A recent clinical trial among HIV-infected adults with per-
sistent diarrhoea showed that 63 % of patients had vitamin
A concentrations consistent with a deficiency state
(,0·7mmol/l) (Kelly et al. 1999).
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Zn is essential for the maturation and differentiation of T
lymphocytes and the functioning of cells mediating non-
specific immunity such as neutrophils and natural killer
cells (Shankar & Prasad, 1998). According to a recent
review, no results have yet been reported regarding the
prevalence of Zn deficiency, as measured by plasma
levels, in HIV-infected patients in Africa (Piwoz &
Preble, 2000). However, low Zn levels (,10·7mmol/l)
have previously been reported in 25–29 % of HIV-infected
adults in the USA (Beach et al. 1992; Koch et al. 1996;
Baum et al. 1997). Such low concentrations of Zn have
been shown to be predictive of HIV disease progression
and mortality (Graham et al. 1991; Baum et al. 1997).
In a search for more cost-effective interventions to reduce
morbidity and mortality in HIV-disease, the identification
and correction of micronutrient deficiencies such as vitamin
A and Zn, may take on increasing importance. A cross-
sectional study was therefore conducted to determine the
plasma vitamin A and Zn levels of HIV-infected adults in
South Africa and to investigate their relationships with
clinical stage, controlling for the acute-phase response.
Methods
The study population consisted of a sample of HIV-
infected adults who attended the Groote Schuur Hospital
(Cape Town) outpatient clinic consecutively between
October 1995 and October 1996 and in whom routine
blood tests were requested by the attending medical prac-
titioner. HIV-seropositivity was confirmed according to
the WHO antibody-testing strategy, namely by means of
three positive enzyme immunoassays (Martin et al.
1995a). Exclusion criteria included anti-retroviral therapy,
current use of vitamin supplements, pregnancy and a clini-
cal diagnosis of liver disease. Patients with pyrexia
(.388C), those who were receiving treatment for an
acute opportunistic infection, as well as patients on therapy
for tuberculosis for ,12 weeks, were also excluded. The
study was approved by the Research and Ethics Committee
at the University of Cape Town.
After written informed consent was obtained, subjects
were interviewed to obtain socio-demographic information
such as educational level, current employment, type of
housing and the availability of electricity or a refrigerator.
The clinical stage of each patient was assessed by a medi-
cal practitioner according to the WHO clinical staging
system (World Health Organization International Collabor-
ating Group for the the Study of the World Health Organ-
ization Staging System, 1993). Body weight was measured
to the nearest 0·1 kg with a beam-balance scale, which was
calibrated at monthly intervals. Subjects were required to
remove heavy clothing and shoes. Height was determined
with a stadiometer to the nearest 1 mm. BMI (kg/m2) was
calculated for each subject.
Venous blood for the determination of plasma retinol, Zn
and C-reactive protein (CRP) was collected between 13·30
and 15·30 hours and subjects were therefore in a fed state.
The puncture site was cleaned with trace-element free alco-
hol to avoid contamination. All specimens were promptly
transported to the laboratory, protected from light and
stored at 2208C after centrifugation, until analysis.
Plasma retinol levels were determined by the fluorometric
method (Underwood, 1990a,b). Duplicate retinol (Sigma
Co., Johannesburgh, South Africa) reference standards
were prepared in ethanol for the spectrofluorophotometer
(E % value: 1835 at 325 nm) for each batch of specimens.
Plasma CRP levels were determined by nephelometry
using an international reference standard for plasma pro-
teins (Behringwerke AG, Marburg, Germany). CRP levels
$10 mg/l were considered to be elevated. Plasma levels
of Zn were measured by atomic absorption spectropho-
tometry (Tietzman, 1987). CD4+ and CD8+ T lymphocyte
counts were measured by a Coulter flow cytometer
(EPICS Profile II, FL, USA).
We estimated that approximately 30 % of our study
population had low plasma retinol levels. To estimate
such a proportion with a precision of 7·5 %, 143 patients
were needed. Clinic records showed that patient attendance
was evenly distributed across clinical strata. Assuming a
difference between strata proportions of #10 %, this
would lead to a x2 test for trend with significance ,5 %.
Statistical analysis
Statistical analysis was performed using Epi-info (version 6;
CDC, Atlanta, GA, USA) and SAS Statistical package, (ver-
sion 6.03; SAS Institute Inc., Cary, NC, USA). Continuous
variables were assessed across clinical stage categories by
the Kruskal–Wallis test due to the non-normality of the
data. Differences in continuous variables between male
and female subjects were assessed by the Wilcoxon rank-
sum test. The relationship between categorical variables
and clinical stage was assessed by the x2 test for trend.
Univariate associations between continuous variables were
performed using the Spearman correlation coefficient.
Multivariate logistic regression was performed using a
stepwise approach, with plasma retinol (,1·05mmol/l)
and Zn (,10·7mmol/l) as binary outcome variables.
Independent variables such as clinical stage, body weight,
CD4+ cell count, haemoglobin, packed cell volume and
CRP levels were examined. The presence of colinearity
(r$0·8) was assessed in order to prevent the inclusion of
strongly correlated variables into the multivariate models.
Results
A total number of 247 HIV-infected patients attended the
clinic during the specified time period; however, routine
blood tests were not requested in thirty-eight patients. Fur-
thermore, seventy-six patients were also excluded accord-
ing to the following criteria: ,18 years old (n 1); the
presence of active opportunistic infection at the time of
the clinic visit (n 10); on current drug therapy for tubercu-
losis for ,12 weeks (n 32); clinical diagnosis of liver dis-
ease (n 3); use of multivitamin supplements at the time or
during the preceding 6 months (n 17); pregnancy (n 9);
prisoners (n 1); problems with venous access (n 3). One
patient refused to participate in the study. None of our sub-
jects were receiving anti-retroviral therapy at the time or
prior to study enrolment.
Results are therefore presented on a total number of 132
patients (Table 1). It has previously been demonstrated
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that patients with WHO stage I and II HIV infection dis-
play similar survival curves (Post et al. 1996). Therefore,
these patients were grouped together during data analysis,
representing early HIV disease. The initial AIDS-defining
illness of stage IV patients and the time period between
the latter and study enrolment, is listed in Table 2. The
mode of transmission for all subjects was heterosexual.
No differences were noted between subjects in the different
clinical stage categories in terms of the different demo-
graphic variables measured. However, only 13 and 14 %
of subjects with stage III and IV disease respectively,
were employed at the time of the study, compared with
43 % of subjects with early disease (P,0·05).
Table 1 shows that the number of patients with low
plasma levels of retinol (,1·05mmol/l) (Pilch, 1987) and
Zn (,10·7mmol/l) (Tietzman, 1987), was significantly
(P,0·001 and P,0·01 respectively) higher among those
with stage III and IV disease, compared with patients
with early disease. The median retinol level for patients
with early disease was 1·19 (interquartile range (IQR)
0·85–1·50) mmol/l, compared with 1·07 (IQR 0·86–1·32)
and 0·83 (IQR 0·59–0·99) mmol/l for those with stage III
and IV disease, respectively (P,0·01). In terms of
plasma Zn, the median level for patients with early disease
was 12·9 (IQR 11·0–15·3) mmol/l, compared with
11·9mmol/l (IQR 9·8–14·1) and 11·0 (IQR 9·2–13·8)
mmol/l for those with stage III and IV disease respectively
(P,0·01).
The median body weight for patients with early disease
was 66·0 (IQR 56·5–78·0) kg, compared with 60·5 (IQR
55·0–66·1) kg and 58·0 (IQR 46·0–65·7) kg for those
with stage III and IV disease respectively (P,0·02).
No sex differences in terms of body weight within the
three clinical staging categories were demonstrated. Due
to incompleteness of data, BMI was determined in 116
patients. Only seven of twenty-nine patients with stage
IV disease had a BMI ,18·5 kg/m2 and could therefore
be categorised as having chronic energy deficiency
(James et al. 1988) (Table 1).
The majority of our patients did not have elevated
plasma CRP levels ($10 mg/l), although a significant
difference was noted across clinical stage categories
(Table 1). Only one patient with stage III disease presented
with a CRP level .100 mg/l. This observation was not
excluded.
We demonstrated weak, positive associations between
CD4+ lymphocyte levels and plasma levels of retinol (r
0·27; 95 % CI 0·10, 0·43) and Zn (r 0·31; 95 % CI 0·25,
0·46), using the Spearman correlation coefficient. Similar
associations were noted between the CD4+ : CD8+ lym-
phocyte ratio and plasma retinol and Zn levels.
Multivariate analysis demonstrated that stage IV disease
was independently associated with a threefold increased
risk of low plasma retinol levels (,1·05mmol/l) after
adjusting for CD4+ lymphocyte count, haemoglobin
levels and body weight (Table 3). Low haemoglobin
levels (,120 g/l) and a decrease in body weight were
both independent predictors of low retinol levels. The
CD4+ lymphocyte count (,200 cells/ml) and
CD4+ : CD8+ lymphocyte ratio (,0·15) were only signifi-
cantly associated during univariate analysis. Plasma Zn and
CRP levels did not contribute significantly to the model,
nor did it change the adjusted odds ratios of any of the
covariates.
Table 1. Characteristics of HIV-infected adults according to World Health Organization clinical staging of HIV-infection*
WHO stage I
and II WHO stage III WHO stage IV
Statistical significance
n % n % n % of effect: P
Age (years)
,30 21 41 22 46 16 49
$ 30 30 59 26 54 17 51
Sex
Male 15 29 17 35 15 45
Female 36 71 31 65 18 55
CD4+ lymphocyte count (cells/ml)
, 200 9 19 26 55 22 69 0·001
$ 200 38 81 21 45 10 31
BMI
, 18·5 2 4 3 7 7 24 0·01
18·5–24·9 22 49 28 66 14 48
$25 21 47 11 27 8 28
Plasma C-reactive protein (mg/l)
, 10 39 77 25 52 19 58 0·05
10–40 11 23 19 40 12 36
. 40 1 2 4 8 2 6
Plasma retinol (mmol/l)
, 1·05 20 39 23 48 26 79 0·001
$ 1·05 31 61 25 52 7 21
Plasma zinc (mmol/l)
, 10·7 10 20 17 36 15 45 0·01
$ 10·7 40 80 30 64 16 55
* For details of classification, see World Health Organization International Collaborating Group for the study of the World Health Organiz-
ation Staging System (1993).
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Table 4 demonstrates that a decrease in body weight was
the only significant independent predictor of low plasma
Zn levels. During univariate analysis, stage IV disease
and a low CD4+ lymphocyte count (,200 cells/ml),
were almost significant. As earlier, the inclusion of CRP
levels did not contribute significantly to the model.
Discussion
The overall prevalence of low plasma retinol concentrations
in our study population was 52 %, which is comparable with
results among infected adults from developing countries
(Semba, 1997; Rwangabwoba et al. 1998). To our knowl-
edge, this is the first study reporting the prevalence of
low plasma Zn levels among HIV-infected adults in
Africa. Although the proportion of asymptomatic patients
who presented with low blood Zn levels was comparable
with previously reported results, a significantly larger
number of patients with advanced disease were deficient
in Zn (P,0·05). A limitation of the present study is that
plasma levels of vitamin A and Zn were not measured in
sero-negative individuals. However, Kafwembe et al.
(2001) demonstrated that HIV-infected individuals in
Zambia were 6·3-times more likely to present with low
vitamin A concentrations, when compared with sero-nega-
tive individuals.
It is likely that several factors contributed to the develop-
ment of micronutrient deficiencies, such as vitamin A and
Zn, in our present study population. Patients with advanced
disease were more likely to be unemployed and therefore,
although we did not assess the dietary intake of vitamin A
and Zn, it is likely that socio-economic factors contributed
to a poorer micronutrient intake in those patients. Rwangab-
woba et al. (1998) demonstrated that among a group of
HIV-infected patients who were co-infected with tuberculo-
sis, patients who presented with weight loss had signifi-
cantly lower vitamin A levels. Only a small number of
our patients were suffering from chronic energy deficiency
ðBMI , 18·5 kg=m2Þ at study entry. However, multivariate
analysis demonstrated that a higher body weight has a sig-
nificant protective effect in terms of the development of a
deficiency in vitamin A and Zn (Tables 3 and 4).
Although we excluded patients with active infections at
the time of study entry, it is likely that previous episodes of
infection may have contributed to the depletion of micro-
nutrient stores, such as retinol (Semba, 1997). During
infections, plasma retinol levels may decrease due to a
poor food intake, an increased utilisation of retinol by
target tissues or via increased urinary losses of vitamin A
(Campos et al. 1987; Stephenson et al. 1994). In addition,
serum concentrations of several nutrients decline during
the acute-phase response, either because they are re-distrib-
uted in the body or because they are bound to acute-phase
proteins. The precise effect of the acute-phase response on
the metabolism of vitamin A is unclear, but it is well docu-
mented that infections result in lowered serum retinol
levels and hepatic vitamin A stores. During the acute-
phase response, plasma Zn and Fe levels also decrease
due to hepatic sequestration, whereas Cu levels increase
due to an increase in caeruloplasmin. Decreased retinol
levels may be caused by a reduced mobilisation of reti-
nol-binding protein from the liver due to hypozincaemia,
since retinol-binding protein is a Zn-dependent protein
(Fleck, 1989; Raynes, 1994). The serum micronutrient
Table 2. Initial AIDS-defining illnesses of World Health Organization clinical stage IV patients*†
(Mean values and standard deviations for twenty-three subjects)
AIDS-defining illness n
Time period between AIDS-defining
illness and study enrolment (months) SD
Extrapulmonary tuberculosis 20 11·2 10·7
Pneumocystis carinii pneumonia 2 3·0 1·4
Cryptococcosis 1 3·0
Toxoplasmosis 1 1·0
Herpes simplex virus 1 0·0
Kaposi’s sarcoma 3 7·3 10·2
Oesophageal candidiasis 3 1·7 2·9
HIV-wasting syndrome 2 0·0
* For details of subjects, see Table 1.
† For details of classification, see World Health Organization International Collaborating Group for the study of
the World Health Organization Staging System (1993).
Table 3. Predictors of plasma retinol levels ,1·05mmol/l in HIV-infected adults*
(Unadjusted and adjusted odds ratios and 95 % confidence intervals)
Variable ORUnadjusted 95 % CI ORAdjusted 95 % CI
WHO clinical stage IV† 4·8 3·0, 7·6 3·4 2·1, 5·7
CD4+ count ,200 cells/ml 3·6 2·4, 5·6 1·4 0·9, 2·1
Haemoglobin ,120 g/l 3·3 2·3, 4·8 2·4 1·6, 3·5
Body weight (per 5 kg decrease) 1·22 1·02, 1·30 1·15 1·08, 1·25
OR, odds ratio.
* For details of subjects and procedures, see Tables 1 and 2.
† For details of classification, see World Health Organization International Collaborating Group for
the study of the World Health Organization Staging Sysem (1993).
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status of HIV-infected individuals with acute infections
should therefore always be interpreted with caution due
to potential misclassification (Fawzi & Hunter, 1998).
In our present study, CRP was measured as a marker of
the acute-phase response. CRP is a non-specific marker of
inflammation or infection and very high plasma CRP con-
centrations (.100 mg/l) are more likely to be associated
with bacterial than viral infections (Young et al. 1991).
Interleukin 6 is thought to be the main mediator of CRP
production (Castell et al. 1990). HIV-infection per se is
known to stimulate macrophages resulting in increased
interleukin 6 levels, even in asymptomatic HIV-positive
patients (Breen et al. 1990). It has been suggested that
interleukin 6 levels increase with the progression of HIV-
infection (Honda et al. 1990). In our present study, a sig-
nificant number of patients with advanced disease had
mildly elevated plasma CRP levels (10–40 mg/l), which
may be attributable to a direct effect of HIV stage I activity
(Table 1). This is consistent with the findings of Tang et al.
(1997) who showed that 55 % of their HIV-infected cohort,
of whom 81 % were asymptomatic, had elevated serum
CRP levels ($8 mg/l). Melchior et al. (1999) recently
demonstrated that CRP was an independent predictor of
survival in a group of HIV-infected patients, who were
free of opportunistic infections at the time of study entry.
They suggested that elevated CRP concentrations may be
related to the rate of virus replication; however, they did
not measure viral load. Serum retinol levels are negatively
associated with elevated CRP levels in adults undergoing
orthopaedic surgery and in schoolchildren with schistoso-
miasis (Louw et al. 1992; Friis et al. 1996). It has been
suggested that low plasma Zn levels are reflective of the
acute-phase response due to HIV-viral activity (Graham
et al. 1991). However, multivariate analysis demonstrated
that CRP was not an independent predictor of low levels
of vitamin A or Zn in our present study.
Lower CD4+ cell counts are associated with low retinol
levels among HIV-infected individuals, while the normali-
sation of retinol and Zn levels have been associated with
higher counts (Semba et al. 1993; Baum et al. 1995). Our
present findings confirmed weak, positive associations
between CD4+ lymphocyte counts and plasma levels of reti-
nol and Zn. The potential confounding effect of tuberculosis
on CD4+ counts was controlled for by restricting our present
sample to patients who had received drug treatment for at
least 12 weeks. A significant rise in CD4+ counts after
that period of time has been demonstrated (Martin et al.
1995b). Retinoids are known to enhance cellular differen-
tiation of haemopoietic cells and the lineage of other cells
(Nuget & Clark, 1985). Thus, retinol status may be import-
ant for the differentiation of CD4+ cells. In human subjects,
Zn deficiency results in rapid and marked atrophy of the
thymus, lymphopaenia and a reduction of primary and sec-
ondary antibody responses, particularly for those antigens
that require T cell help (Shankar & Prasad, 1998).
Our present findings demonstrate that patients with
WHO stage IV disease had a threefold risk of having
plasma retinol levels ,1·05mmol/l, after adjusting for
CD4+ lymphocyte count, body weight and haemoglobin
levels (Table 3). On the other hand, a decrease in body
weight was the only significant predictor of low Zn
levels in our present study (Table 4). CD4+ lymphocyte
count and the CD4+ : CD8+ lymphocyte ratio were not
independent predictors of a low retinol status in the present
study, after adjusting for clinical stage. Reduced haemo-
globin and packed cell volume levels have been associated
with low serum retinol levels in HIV-infected patients
(Semba et al. 1993, 1995). Haemoglobin may be an inter-
mediate variable in the relationship between vitamin A and
AIDS, since haematopoiesis is vitamin A-dependent. It
appears that vitamin A-deficient children are prone to the
development of a mild Fe-deficiency anaemia and that vita-
min A supplementation may improve haematopoiesis in
children who are vitamin A deficient. Vitamin A may
therefore be involved in the regulation of Fe release from
hepatic stores (Meijia & Chew, 1988; Semba et al. 1992).
CD4+ lymphocyte counts are a standard laboratory
marker of disease progression in HIV infection, but
expense precludes their use in many resource-poor settings
in Africa. We demonstrated that WHO clinical stage IV
HIV disease was a stronger predictor of low plasma con-
centrations of micronutrients, such as vitamin A, than
CD4+ cell counts in our present study population. It
could thus be argued that these patients might be targeted
for micronutrient supplementation by practitioners at a pri-
mary-care level. However, it must be noted that our cross-
sectional study design precludes any causal inferences
about the association between plasma vitamin A and Zn
status and the progression of HIV disease.
High-dose vitamin A supplementation has been shown to
reduce diarrhoeal disease morbidity and AIDS-related mor-
tality in HIV-infected children, and improve the CD4+ cell
counts of children with AIDS (Coutsoudis et al. 1995;
Hussey et al. 1996; Fawzi et al. 1999). In contrast, the
short-term administration of high doses of vitamin A
in HIV-infected adults did not increase CD4+ counts.
The HIV viral load remained unchanged. However, only a
small number of adults in two of the three studies cited
Table 4. Predictors of plasma zinc levels ,10·7mmol/l in HIV-infected adults*
(Unadjusted and adjusted odds ratios and 95 % confidence intervals)
Variable ORUnadjusted 95 % CI ORAdjusted 95 % CI
WHO clinical stage IV† 2·2 0·94, 4·90 2·2 0·9, 6·0
CD4+ count ,200 cells/ml 2·2 1·0, 4·8 1·4 0·6, 3·2
Body weight (per 5 kg decrease) 1·19 1·10, 1·28 1·19 1·09, 1·30
OR, odds ratio.
* For details of subjects and procedures, see Tables 1 and 2.
† For details of classification, see World Health Organization International Collaborating Group for
the Study of the World Health Organization Staging System (1993).
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had plasma vitamin A levels that were consistent with
deficiency (Coutsoudis, 1997; Semba et al. 1998;
Humphrey et al. 1999). High circulating HIV viral load
has been shown to be a risk factor for HIV progression
(Ferre et al. 1995). It has been suggested that vitamin A
deficiency and viral load may be independent risk factors
for the progression of HIV disease (Semba, 1997). Several
clinical trials have documented the lack of a beneficial
effect of vitamin A supplementation on reducing the
mother-to-child transmission of HIV. In view of these find-
ings, it has been suggested that serum retinol concentrations
may be merely markers of HIV-disease severity, which is an
important predictor of vertical transmission (Semba, 1997;
Coutsoudis et al. 1999; Fawzi et al. 2000). However,
other potential biological mechanisms still remain, whereby
vitamin A supplementation may be beneficial in reducing
morbidity and mortality in HIV disease.
Zn supplementation has been demonstrated to increase
the efficiency of the immune system in a number of study
populations, including marasmic infants (Castillo-Duran
et al. 1987), and children recovering from malnutrition
(Golden & Golden, 1981). A recent meta-analysis showed
that Zn has a major role to play in the primary prevention
of diarrhoeal disease and acute lower respiratory tract
infections in children from developing countries. (Zinc
Investigators’ Collaborative Group, 1999). Few Zn supple-
mentation studies have been conducted in HIV–AIDS
patients. Supplementation for 1 month of adults with
AIDS on zidovudine therapy resulted in the stabilisation
of body weight, as well as increases in CD4+ cell count
and plasma levels of Zn-bound thymulin. A marked
reduction in opportunistic infections in the Zn-treated
group was also demonstrated (Mocchegiani et al. 1995).
Conclusion
Our present findings suggest that low plasma concentrations
of vitamin A and Zn are common among HIV-infected
adults attending an outpatient health facility in South
Africa. We showed that patients with advanced disease
and/or weight loss were more likely to present with low
plasma levels, even in the absence of any opportunistic
infection, especially in the case of plasma retinol levels.
At present, it is not known whether low serum or plasma
levels merely reflect disease progression or whether they
indicate true micronutrient deficiencies. Clinical trials are
needed to evaluate the safety and effectiveness of micro-
nutrient supplements such as vitamin A and Zn on the
progression of HIV disease in developing countries, where
the majority of HIV-infected individuals are likely to have
a marginal micronutrient status. In sub-Saharan Africa,
where antiretroviral therapies are prohibitively expensive,
the optimisation of micronutrient status may be among the
affordable strategies available to improve the morbidity
and mortality of HIV-infected adults and children.
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